- Home
- CATX vs FLGT Comparison
CATX vs FLGT Comparison
Compare CATX & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- FLGT
- Stock Information
- Founded
- CATX 1983
- FLGT 2011
- Country
- CATX United States
- FLGT United States
- Employees
- CATX N/A
- FLGT N/A
- Industry
- CATX Medical/Dental Instruments
- FLGT Medical Specialities
- Sector
- CATX Health Care
- FLGT Health Care
- Exchange
- CATX Nasdaq
- FLGT Nasdaq
- Market Cap
- CATX 782.7M
- FLGT 683.5M
- IPO Year
- CATX N/A
- FLGT 2016
- Fundamental
- Price
- CATX $3.07
- FLGT $19.44
- Analyst Decision
- CATX Strong Buy
- FLGT Hold
- Analyst Count
- CATX 9
- FLGT 1
- Target Price
- CATX $17.25
- FLGT $22.00
- AVG Volume (30 Days)
- CATX 2.7M
- FLGT 257.8K
- Earning Date
- CATX 11-12-2024
- FLGT 11-08-2024
- Dividend Yield
- CATX N/A
- FLGT N/A
- EPS Growth
- CATX N/A
- FLGT N/A
- EPS
- CATX N/A
- FLGT N/A
- Revenue
- CATX $1,557,000.00
- FLGT $277,761,000.00
- Revenue This Year
- CATX N/A
- FLGT N/A
- Revenue Next Year
- CATX N/A
- FLGT $16.00
- P/E Ratio
- CATX N/A
- FLGT N/A
- Revenue Growth
- CATX N/A
- FLGT N/A
- 52 Week Low
- CATX $2.50
- FLGT $16.56
- 52 Week High
- CATX $19.10
- FLGT $30.68
- Technical
- Relative Strength Index (RSI)
- CATX 20.31
- FLGT 49.39
- Support Level
- CATX $3.27
- FLGT $19.25
- Resistance Level
- CATX $3.60
- FLGT $21.36
- Average True Range (ATR)
- CATX 0.33
- FLGT 0.87
- MACD
- CATX 0.21
- FLGT 0.09
- Stochastic Oscillator
- CATX 0.00
- FLGT 42.51
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.